Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors
NCT05687110Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of novobiocin in solid tumor, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose and Recommended Phase 2 Dose up to 2 years. Started Jul 2023; status: recruiting.
02
Drugs
novobiocin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05687110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687110.